KKR agreed to acquire Integer Holdings Corporation in an all-cash transaction valuing the medical device component manufacturer at $5.7 billion including debt, removing the Texas-based supplier from public markets as buyout shops continue aggressive positioning in healthcare infrastructure. The deal, announced Wednesday, represents a 42% premium to Integer's thirty-day volume-weighted average share price and marks one of the larger healthcare take-privates since the Federal Reserve pivoted from its tightening cycle.
Integer manufactures components for cardiac rhythm management devices, neuromodulation systems, and advanced surgical tools—selling into Boston Scientific, Medtronic, Abbott, and other large-cap med-tech names. The company reported $1.52 billion in revenue for the twelve months ending September 2024, with operating margins in the mid-teens. KKR is acquiring stable cash flow and entrenched relationships inside a regulatory-moated sector where switching costs run high and product cycles stretch across years. The transaction includes Integer's entire portfolio, including its Greatbatch Medical and Lake Region Medical divisions, both legacy assets with deep manufacturing scale.
The move reflects continued private equity appetite for non-branded healthcare infrastructure plays—companies that sit one layer below the device OEMs and benefit from secular procedure volume growth without bearing the full weight of FDA approval timelines or reimbursement risk. KKR has deployed over $20 billion in healthcare since 2020, including takes on Envision Healthcare, Cotiviti, and a minority stake in Syneos Health before its later sale. Integer fits the pattern: defensible margins, long-term contracts, and limited exposure to consumer-facing brand risk. The transaction also removes a public equity float that had traded sideways for eighteen months as growth investors rotated out of mid-cap industrials into AI and semiconductors.
Operators and allocators should watch for two follow-on developments. First, whether KKR consolidates Integer with other portfolio assets in adjacent supply chain nodes—particularly surgical tool OEMs or battery technology platforms—within the next twelve to eighteen months. Second, how Integer's customer base responds to the ownership change, especially regarding supply assurance and capital investment in next-generation manufacturing capacity. Boston Scientific and Medtronic both source heavily from Integer; any pause in capex or delivery timelines could create short-term volatility in their component procurement.
The deal is expected to close mid-2025, subject to shareholder approval and regulatory clearance. Integer's management team remains in place, a signal KKR intends operational continuity rather than restructuring. The financing package has not been disclosed, but given current leverage multiples in healthcare services trades, expect debt in the 5.0x to 5.5x EBITDA range, with the rest in equity from KKR's latest flagship fund.